Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
YANG Sun, PHD
CONTACT
Lead
Fujian Cancer Hospital
With
Patients with platinum-resistant relapsed/metastatic ovarian cancer are treated with adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy for 6 cycles followed by maintenance therapy with adebrelimab plus fluzoparib
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted